# A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme

> **NCT00800917** · PHASE2 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 12 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00800917
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2010-06-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00800917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00800917, "A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00800917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*